NASDAQ:VRAX - KYG9495L1251 - Common Stock
The current stock price of VRAX is 0.5711 USD. In the past month the price decreased by -31.19%. In the past year, price decreased by -83.73%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
MCK | MCKESSON CORP | 20.66 | 86.02B | ||
COR | CENCORA INC | 19.03 | 57.17B | ||
CAH | CARDINAL HEALTH INC | 18.15 | 35.71B | ||
HSIC | HENRY SCHEIN INC | 14.68 | 8.29B | ||
AHCO | ADAPTHEALTH CORP | 29.52 | 1.24B | ||
AHG | AKSO HEALTH GROUP | N/A | 933.64M | ||
OMI | OWENS & MINOR INC | 3.65 | 411.69M | ||
WGRX | WELLGISTICS HEALTH INC | N/A | 117.68M | ||
ATPC | AGAPE ATP CORP | N/A | 66.01M | ||
COSM | COSMOS HEALTH INC | N/A | 23.84M |
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
VIRAX BIOLABS GROUP LTD
Biocity Glasgow, Bo'ness Road, Newhouse
London GB
Employees: 19
Phone: 4402077887414
The current stock price of VRAX is 0.5711 USD. The price decreased by -5.73% in the last trading session.
The exchange symbol of VIRAX BIOLABS GROUP LTD is VRAX and it is listed on the Nasdaq exchange.
VRAX stock is listed on the Nasdaq exchange.
VIRAX BIOLABS GROUP LTD (VRAX) has a market capitalization of 2.48M USD. This makes VRAX a Nano Cap stock.
VIRAX BIOLABS GROUP LTD (VRAX) currently has 19 employees.
VIRAX BIOLABS GROUP LTD (VRAX) has a resistance level at 0.68. Check the full technical report for a detailed analysis of VRAX support and resistance levels.
The Revenue of VIRAX BIOLABS GROUP LTD (VRAX) is expected to grow by 66.97% in the next year. Check the estimates tab for more information on the VRAX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VRAX does not pay a dividend.
VIRAX BIOLABS GROUP LTD (VRAX) will report earnings on 2022-12-13, before the market open.
VIRAX BIOLABS GROUP LTD (VRAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
The outstanding short interest for VIRAX BIOLABS GROUP LTD (VRAX) is 1.05% of its float. Check the ownership tab for more information on the VRAX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to VRAX. The financial health of VRAX is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months VRAX reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 50.82% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -94.31% | ||
ROE | -106.41% | ||
Debt/Equity | 0.06 |
For the next year, analysts expect an EPS growth of 166.67% and a revenue growth 66.97% for VRAX